search
Back to results

Examining Carryover Effect in Patients Treated witH Spinal cOrd Stimulation (ECHO) (ECHO)

Primary Purpose

Neuralgia, Spinal Cord Stimulation

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Temporary device deactivation
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Neuralgia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patient age minimum 18 years
  • signed informed consent
  • implanted with full SCS system for neuropathic pain
  • SCS treatment duration minimum 6 months before inclusion
  • maximum pain score 7 or less on a 0-10 NRS at the area of pain treated with SCS during the last 48 hours before study-related deactivation of the device

Exclusion Criteria

  • any surgical SCS lead revision for the last 6 months before inclusion
  • any changes in the programming patterns of the device (except patient-controlled changes in amplitude) for a minimum of 30 days before the study-related deactivation of the device
  • any other ongoing neuromodulatory treatment (PNS, TENS, etc.)
  • any other neuromodulatory treatment with lasting effect (RFA, sympathectomy, infiltration anesthesia, nerve blockade) within the last 60 days
  • any changes in analgetic medication within the last 30 days (pn. dosings are allowed)

Sites / Locations

  • AZ Delta Roeselare/Menen/Torhout
  • CHU de Québec - Université Laval
  • Aalborg University Hospital
  • Aarhus University Hospital
  • Odense University Hospital
  • Diakovera Friederikenstift
  • Medisch Spectrum Twente
  • Erasmus University Medical Center
  • Sahlgrenska University Hospital
  • Sunderby Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intervention

Arm Description

Temporary device deactivation

Outcomes

Primary Outcome Measures

Carryover/echo effect: Time from deactivation of device to cessation of treatment affect
Time from deactivation of device to cessation of treatment affect

Secondary Outcome Measures

Reverse carryover/echo effect: Time from reactivation of device to full reestablishment of treatment effect
Time from reactivation of device to full reestablishment of treatment effect

Full Information

First Posted
December 6, 2017
Last Updated
May 12, 2021
Sponsor
University of Aarhus
Collaborators
Aarhus University Hospital, CHU de Quebec-Universite Laval, Medisch Spectrum Twente, Odense University Hospital, Aalborg University Hospital, Sahlgrenska University Hospital, Sweden, Diakoniekrankenhaus Friederikenstift, Sunderby Hospital, Erasmus Medical Center, AZ Delta
search

1. Study Identification

Unique Protocol Identification Number
NCT03386058
Brief Title
Examining Carryover Effect in Patients Treated witH Spinal cOrd Stimulation (ECHO)
Acronym
ECHO
Official Title
Examining Carryover Effect in Patients Treated witH Spinal cOrd Stimulation (ECHO). An Open, Prospective, Multicenter Study.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
January 31, 2018 (Actual)
Primary Completion Date
March 30, 2021 (Actual)
Study Completion Date
March 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus
Collaborators
Aarhus University Hospital, CHU de Quebec-Universite Laval, Medisch Spectrum Twente, Odense University Hospital, Aalborg University Hospital, Sahlgrenska University Hospital, Sweden, Diakoniekrankenhaus Friederikenstift, Sunderby Hospital, Erasmus Medical Center, AZ Delta

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Spinal cord stimulation is a minimally invasive surgical treatment for severe, chronic, neuropathic pain that is refractory to conventional treatment. The treatment consists of an electrode implanted in the epidural space of the spinal cord, either via a percutaneous approach (using the so-called percutaneous leads) or via a surgical (hemi-) laminectomy (using the so-called surgical leads or plate leads). It is a well-known clinical observation that when activating or deactivating SCS stimulation, there is a variable interval before the patient perceives a clinical effect of the change. This variation goes by different names (carryover, echo, after effect, etc.) and might be dependent on the clinical condition and treatment duration. To our knowledge only very little research has been published on the topic of carryover effects; a recent study showed that the interval is highly variable between patients. While patients may experience immediate pain relief at the onset of SCS treatment, the effect in patients with a long-term SCS treatment history may have different characteristics, possibly due to ongoing changes in the nervous system. The aim of this pilot study is to lay the foundation for investigating the carryover effects in spinal cord stimulation. This will be carried out in a mixed population of patients with different indications for SCS, and with different treatment durations. Patients will be asked to deactivate their device via their remote control or with a magnet in a standardized fashion. They will be asked to reactivate the device when specific parameters have been met, and the time is recorded.
Detailed Description
In the post-hoc analysis the carryover and reverse carryover effect will be analyzed and correlated to a number of parameters including, but not limited to: Indication, treatment duration, symptom duration, preoperative pain score, stimulation paradigm, gender, age. Data will be collected and stored using a dedicated REDCap database under the auspices of Aarhus University.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuralgia, Spinal Cord Stimulation

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Open study
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Temporary device deactivation
Intervention Type
Device
Intervention Name(s)
Temporary device deactivation
Intervention Description
Patient-controlled, temporary deactivation of implanted device
Primary Outcome Measure Information:
Title
Carryover/echo effect: Time from deactivation of device to cessation of treatment affect
Description
Time from deactivation of device to cessation of treatment affect
Time Frame
Up to one week (may be repeated)
Secondary Outcome Measure Information:
Title
Reverse carryover/echo effect: Time from reactivation of device to full reestablishment of treatment effect
Description
Time from reactivation of device to full reestablishment of treatment effect
Time Frame
Up to one week (may be repeated)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patient age minimum 18 years signed informed consent implanted with full SCS system for neuropathic pain SCS treatment duration minimum 6 months before inclusion maximum pain score 7 or less on a 0-10 NRS at the area of pain treated with SCS during the last 48 hours before study-related deactivation of the device Exclusion Criteria any surgical SCS lead revision for the last 6 months before inclusion any changes in the programming patterns of the device (except patient-controlled changes in amplitude) for a minimum of 30 days before the study-related deactivation of the device any other ongoing neuromodulatory treatment (PNS, TENS, etc.) any other neuromodulatory treatment with lasting effect (RFA, sympathectomy, infiltration anesthesia, nerve blockade) within the last 60 days any changes in analgetic medication within the last 30 days (pn. dosings are allowed)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kaare Meier, MD PhD
Organizational Affiliation
Aarhus University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
AZ Delta Roeselare/Menen/Torhout
City
Roeselare
ZIP/Postal Code
8800
Country
Belgium
Facility Name
CHU de Québec - Université Laval
City
Quebec City
State/Province
Quebec
ZIP/Postal Code
G1J 1Z6
Country
Canada
Facility Name
Aalborg University Hospital
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Facility Name
Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
8000
Country
Denmark
Facility Name
Odense University Hospital
City
Odense
ZIP/Postal Code
5230
Country
Denmark
Facility Name
Diakovera Friederikenstift
City
Hannover
ZIP/Postal Code
30169
Country
Germany
Facility Name
Medisch Spectrum Twente
City
Enschede
State/Province
Overijssel
ZIP/Postal Code
7512 KZ
Country
Netherlands
Facility Name
Erasmus University Medical Center
City
Rotterdam
ZIP/Postal Code
3000CA
Country
Netherlands
Facility Name
Sahlgrenska University Hospital
City
Göteborg
ZIP/Postal Code
413 45
Country
Sweden
Facility Name
Sunderby Hospital
City
Luleå
ZIP/Postal Code
97180
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22151660
Citation
Wolter T, Winkelmuller M. Continuous versus intermittent spinal cord stimulation: an analysis of factors influencing clinical efficacy. Neuromodulation. 2012 Jan-Feb;15(1):13-9; discussion 20. doi: 10.1111/j.1525-1403.2011.00410.x. Epub 2011 Dec 12.
Results Reference
background
PubMed Identifier
23425338
Citation
Perruchoud C, Eldabe S, Batterham AM, Madzinga G, Brookes M, Durrer A, Rosato M, Bovet N, West S, Bovy M, Rutschmann B, Gulve A, Garner F, Buchser E. Analgesic efficacy of high-frequency spinal cord stimulation: a randomized double-blind placebo-controlled study. Neuromodulation. 2013 Jul-Aug;16(4):363-9; discussion 369. doi: 10.1111/ner.12027. Epub 2013 Feb 20.
Results Reference
background

Learn more about this trial

Examining Carryover Effect in Patients Treated witH Spinal cOrd Stimulation (ECHO)

We'll reach out to this number within 24 hrs